Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of maternal GBS6 vaccination in pregnant women and their infants
2022-503070-36-00Phase 3Authorised
- Sponsor
- Pfizer
- Start
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in Streptococcus agalactiae infection (GBS) comparing GBS6 vaccine with Placebo (2 arms). Primary endpoints: Prespecified local reactions, Prespecified systemic events and 5 more. Planned start Dec 2025; status: authorised.
02
Drugs
GBS6
03
Conditions
Streptococcus agalactiae infection (GBS)
Beyond the preview
Go deeper on 2022-503070-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503070-36-00.